https://www.selleckchem.com/pr....oducts/Acetylcholine
88 QALY. This is confirmed by both the deterministic and probabilistic sensitivity analyses. The main limit of the study remains the absence of long-term clinical data allowing to relate treatment consumption to clinical benefit, especially in the progression of haemophilic arthropathy. Our results show that emicizumab is a cost-effective treatment allowing to consider an easy to implement prophylactic treatment for haemophilia A patients with anti-FVIII inhibitors. Our results show that emicizumab is a cost-effective tre
Curtir
Comentario
Compartilhar
